RxDoctor Payments Data

Jonathan Lauritsen, DO

Neurology · Plano, TXNPI 1346773017

Payments from drug & device makers

$6,714in general payments, 2019–2025

Across 296 payments — averaging $22.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$754
  • UCB, Inc.$402
  • Lilly USA, LLC$391
  • SK Life Science, Inc.$257
  • Teva Pharmaceuticals USA, Inc.$247
  • Genentech USA, Inc.$227
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$6,60098%
  • Education$1142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie50$754
UCB, Inc.14$402
Lilly USA, LLC18$391
SK Life Science, Inc.10$257
Teva Pharmaceuticals USA, Inc.8$247
Genentech USA, Inc.9$227
EMD Serono, Inc.6$205
AstraZeneca7$194
Novartis7$193
Biogen8$185
CSL Behring4$170
Argenx US, Inc.6$163
Lundbeck LLC6$156
Neurocrine Biosciences, Inc.6$146
Sanofi6$139
Pfizer7$138
Amneal Pharmaceuticals LLC6$132
Grifols USA, LLC6$130
MDD US Operations, LLC5$123
ANI Pharmaceuticals, Inc.4$111
Upsher-smith Laboratories LLC5$111
Bristol Myers Squibb5$107
Otsuka America Pharmaceutical, Inc.5$106
Axsome Therapeutics, Inc.5$104
Mallinckrodt Hospital Products Inc.5$96
Jazz Pharmaceuticals Inc.4$93
Merz Pharmaceuticals, LLC3$88
Scilex Pharmaceuticals Inc.5$88
Boston Scientific3$81
Abbott4$79
Siemens Medical Solutions USA, Inc.1$78
Sumitomo Pharma America, Inc.5$69
GE HealthCare3$64
Tanabe Pharma America, Inc.3$63
Amgen(2 entities)3$58
Azurity Pharmaceuticals, Inc.3$57
Eisai Inc.2$55
Biohaven Pharmaceutical Holding Company Ltd.3$51
Acorda Therapeutics, Inc2$50
Takeda Pharmaceuticals U.S.A., Inc.2$50
Neurelis, Inc.2$48
Sunovion Pharmaceuticals Inc.2$45
Kyowa Kirin, Inc.2$44
Impel Pharmaceuticals Inc.2$44
Harmony Biosciences LLC2$41
Biohaven Pharmaceuticals, Inc.2$41
E.r. Squibb & Sons, L.L.C.2$40
Avadel CNS Pharmaceuticals, LLC2$39
Avion Pharmaceuticals2$37
Collegium Pharmaceutical, Inc.2$36
ZOLL Respicardia, Inc.1$35
Averitas Pharma Inc.1$32
TG Therapeutics, Inc.1$30
Corium, LLC1$30
Aprecia Pharmaceuticals, LLC1$25
Merck1$25
Aucta Pharmaceuticals, Inc.1$24
Microtransponder, Inc.1$22
Chiesi USA, Inc.1$20
Idorsia Pharmaceuticals US Inc1$17

How this compares

$6,714 in reported general payments places this provider in the 60th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$152,709
Medicare patients
392
Services billed
5,080

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine13$87,804
NuplazidPimavanserin Tartrate12$78,683
RytaryCarbidopa/Levodopa22$33,980
Emgality PenGalcanezumab-Gnlm17$23,003
Glatiramer Acetate12$16,651
Carbidopa-LevodopaCarbidopa/Levodopa114$5,918
Donepezil Hcl383$4,416
Memantine Hcl111$3,756
Galantamine ErGalantamine Hbr52$3,453
Gabapentin126$3,274
Pregabalin81$2,430
Propranolol Hcl79$2,133
Lacosamide36$2,046
Baclofen13$1,893
Sumatriptan Succinate64$1,779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$247$87,80413 claims
Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil$132$34,62034 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,246 neurology providers in Texas.

Other neurology in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →